Stimulation of erythrocyte phosphatidylserine exposure by chlorpromazine.
Side effects of treatment with chlorpromazine include anaemia which could result from decreased formation or accelerated clearance of circulating erythrocytes. Recently, a novel mechanism leading to erythrocyte clearance has been disclosed. Osmotic shock, oxidative stress and glucose deprivation lead to activation of cation channels, Ca(2+) entry, activation of a Ca(2+)-sensitive erythrocyte scramblase and subsequent exposure of phosphatidylserine at the erythrocyte surface. As macrophages are equipped with phosphatidylserine receptors, they bind, engulf and degrade phosphatidylserine exposing cells. The present experiments have been performed to explore whether chlorpromazine triggers phosphatidylserine exposure of erythrocytes. The phosphatidylserine exposure was estimated from annexin binding as determined in fluorescence activated cell sort (FACS) analysis. A 24 h exposure to glucose-free medium decreased cytosolic ATP levels, decreased cellular levels of reduced glutathione (GSH) and increased annexin binding. The effect on annexin binding and ATP but not on GSH was significantly enhanced in the presence of chlorpromazine (10 microM). Higher concentrations of chlorpromazine (40 microM) increased cytosolic Ca(2+) activity. Osmotic shock and Cl(-) removal similarly increased annexin binding, effects again being enhanced in the presence of chlorpromazine. In conclusion, the present observations point to a novel side effect of chlorpromazine, i.e. increased sensitivity of erythrocytes to glucose deprivation. The effect could well contribute to the known anaemia observed in the treatment with this antipsychotic drug.
Akel
Ahmad
A
Department of Physiology, University of Tübingen, Gmelinstrasse 5, D-72076 Tübingen, Germany.
Hermle
Tobias
T
Niemoeller
Olivier M
OM
Kempe
Daniela S
DS
Lang
Philipp A
PA
Attanasio
Philipp
P
Podolski
Marlis
M
Wieder
Thomas
T
Lang
Florian
F
D000255:Adenosine Triphosphate / Q000378:metabolism; D014150:Antipsychotic Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002712:Chlorides / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D005434:Flow Cytometry / Q000379:methods; D005947:Glucose / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D006982:Hypertonic Solutions / Q000494:pharmacology; D007552:Isotonic Solutions / Q000494:pharmacology; D010718:Phosphatidylserines / Q000378:metabolism*
D014150:Antipsychotic Agents; D002712:Chlorides; D006982:Hypertonic Solutions; D007552:Isotonic Solutions; D010718:Phosphatidylserines; D000255:Adenosine Triphosphate; D005978:Glutathione; D005947:Glucose; D002118:Calcium; D002746:Chlorpromazine